Please assess the completion status of the following clinical trial:

Trial Title: A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Moderate-to-severe rosacea (as per the IGA score) on the proposed facial treatment area consisting of:~   1. At least 15 and not more than 75 facial papules and pustules, excluding lesions involving the eyes and scalp;~  2. No more than 2 nodules on the face.~2. Presence of or history of erythema and/or flushing on the face.~Exclusion Criteria:~1. Presence of any skin condition and/or Excessive facial hair, on the face that would interfere with the diagnosis or assessment of rosacea.~2. Moderate or severe rhinophyma, dense telangiectasia (score 3, severe), or plaque-like facial edema.~3. History of hypersensitivity or allergy to minocycline, any other tetracycline, or of any other component of the formulation.~4. Active ocular rosacea (eg, conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMX103 1.5% (Type: EXPERIMENTAL): Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
- Vehicle foam (Type: PLACEBO_COMPARATOR): Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.

Based on this trial design, predict the completion outcome and termination type (if applicable).